Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

NCT01985724 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

650

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Docetaxel
DRUG: Epirubicin
DRUG: Cyclophosphamide
DRUG: 5-fluoruracil
DRUG: Granulocyte-colony stimulating growth factor

Sponsor

Hellenic Oncology Research Group

Collaborators

[object Object]